Icecure Medical
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 syst… Read more
Icecure Medical (ICCM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.291x
Based on the latest financial reports, Icecure Medical (ICCM) has a cash flow conversion efficiency ratio of -0.291x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.71 Million) by net assets ($9.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Icecure Medical - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Icecure Medical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Icecure Medical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icecure Medical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Synergy Green Industries Limited
NSE:SGIL
|
0.056x |
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
-1.469x |
|
Poznanska Korporacja Budowlana Pekabex SA
WAR:PBX
|
-0.137x |
|
SRV Group plc
HE:SRV1V
|
0.076x |
|
Everyday People Financial Corp.
V:EPF
|
-0.083x |
|
Excellon Resources Inc
PINK:EXNRF
|
-0.033x |
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
N/A |
|
Xtant Medical Holdings Inc
NYSE MKT:XTNT
|
0.092x |
Annual Cash Flow Conversion Efficiency for Icecure Medical (2014–2024)
The table below shows the annual cash flow conversion efficiency of Icecure Medical from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.90 Million | $-12.56 Million | -1.820x | -76.84% |
| 2023-12-31 | $12.16 Million | $-12.52 Million | -1.029x | -83.11% |
| 2022-12-31 | $25.42 Million | $-14.29 Million | -0.562x | -20.23% |
| 2021-12-31 | $26.96 Million | $-12.61 Million | -0.468x | +41.93% |
| 2020-12-31 | $4.58 Million | $-3.69 Million | -0.805x | -21.39% |
| 2019-12-31 | $2.63 Million | $-1.74 Million | -0.663x | +27.11% |
| 2018-12-31 | $3.37 Million | $-3.06 Million | -0.910x | -108.91% |
| 2017-12-31 | $-256.93K | $-2.62 Million | 10.216x | +786.08% |
| 2016-12-31 | $2.10 Million | $-3.13 Million | -1.489x | -71.13% |
| 2015-12-31 | $3.85 Million | $-3.35 Million | -0.870x | +52.68% |
| 2014-12-31 | $1.84 Million | $-3.39 Million | -1.839x | -- |